AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Go Back to All Clinical Trials

AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Brief description of study

The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk (HR) B-ALL or NCI Standard Risk (SR) B-ALL with certain high risk features. Part 1 of the study is to collect information about your leukemia and chemotherapy is used to try to remove all visible signs of leukemia and allow normal blood cell production to be restored. Depending on your risk group, you may participate in Part II of the study and receive the investigational medicine. There are no experimental medicines that will be given during Part 1 of the study.

Clinical Study Identifier: s19-01764

ClinicalTrials.gov Identifier: NCT03959085

Principal Investigator: Chana Glasser.

Other Investigators: Mark E Weinblatt, Lia Phillips, Christeen Azmy, Sylwia Jasinski, Joshua Isao Chan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies